Insight

Incorporation of immunotherapy in the management of early-stage ER+ Breast Cancer

Collage photo of Guilherme Nader-Marta, Adrienne Waks, Sara Tolaney, Erica Mayer

Nov 10, 2024, 16:37

Incorporation of immunotherapy in the management of early-stage ER+ Breast Cancer

A recent paper by Guilherme Nader-Marta, Clinical Fellow at Dana-Farber Cancer Institute, was mentioned by Dana-Farber’s Breast Oncology Center on X:

“Check out this new editorial in ESMO Open on the incorporation of immunotherapy in the management of early-stage estrogen receptor-positive Breast Cancer.”

“Incorporating immunotherapy in the management of early-stage estrogen receptor-positive breast cancer”

Authors: Guilherme Nader-Marta, Adrienne Waks, Sara Tolaney, Erica Mayer.

Posts featuring Dana-Farber’s Breast Oncology Center

Adrienne Waks cancer Dana-Farber’s Breast Oncology Center ER+ breast cancer Erica Mayer ESMO Open Guilherme Nader Marta OncoDaily Oncology Sara Tolaney

Agenus Bets Big on Botensilimab

Carlos Rodriguez-Galindo: Childhood cancer has long been overlooked in global strategies - It is time to change that

EMBER-3 Trial Updates from ESMO Breast 2025: Imlunestrant Plus Abemaciclib Improves PFS in CDK4/6i-Pretreated ER+/HER2- Breast Cancer

FDA Grants Accelerated Approval for Telisotuzumab Vedotin (EMRELIS™) in c-MET–Overexpressing Advanced Non-Small Cell Lung Cancer

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research